A phase IIa, double-blind, placebo-controlled, randomised, parallel-design, four-week study to investigate the safety and efficacy of the oral renin inhibitor SPP635 once daily in patients with mild to moderate hypertension

Trial Profile

A phase IIa, double-blind, placebo-controlled, randomised, parallel-design, four-week study to investigate the safety and efficacy of the oral renin inhibitor SPP635 once daily in patients with mild to moderate hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs SPP 635 (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2008 Results presented at Hypertension 2008 according to a Speedel media release (9090328).
    • 02 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top